• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Redeye: Arise (Q3 Review) - Eventful months to come

ArisePress release07.11.2025, 08.49

Redeye adjusts its estimates and fair value range following Arise’s Q3 report. We believe the report had numerous moving parts, making the reported numbers somewhat difficult to grasp at first glance. However, adjusted for all effects, we conclude that the underlying Q3 numbers were largely in line with our estimates. Apart from the adjustments, we have also gained some clarity on the paused revenue recognition of Fasikan and the potential 400MW AI data centre, which is still in its early stages but could generate a profit exceeding Arise’s current market cap several times over. We also believe that there is a risk that Arise may not reach its implicit target of divesting more than 265MW in Q4 2025. Consequently, we expect this to result in a slight shift in timing, pushing volumes into Q1 2026.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


Arise (Q3 Review) - Eventful months to come